Translating NIA-AA criteria into usual practice: Report from the ReDeMa Project.

Area of Science:

• Neurology
• Biomarkers
• Alzheimer's Disease Diagnostics

Background:

• The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) proposed biomarker-informed criteria for Alzheimer's disease (AD) diagnosis.
• The clinical utility and adequacy of these NIA-AA criteria require further evaluation in real-world settings.

Purpose of the Study:

• To evaluate the adequacy and impact of the 2011 NIA-AA diagnostic criteria in a regional cohort of dementia patients.
• To assess the influence of cerebrospinal fluid (CSF) biomarkers on diagnostic confidence and patient management.

Main Methods:

• Analysis of 233 patients from the ReDeMa (Red de Demencias de Madrid) cohort.
• Collection of core CSF biomarkers and application of NIA-AA diagnostic criteria.
• Evaluation of changes in diagnosis and clinical management.

Main Results:

• The NIA-AA criteria were adopted in 69% of cases, significantly increasing diagnostic confidence from 70% to 92%.
• Clinical management was altered in 71% of patients/caregivers.
• Neurologist's age or expertise had minimal influence on the study outcomes.

Conclusions:

• The 2011 NIA-AA criteria are adequate and useful for routine practice in memory and neurology clinics.
• The integration of CSF biomarkers enhances diagnostic certainty and positively impacts patient management strategies for Alzheimer's disease.